ClinicalTrials.gg
RecruitingNCT06194734Updated Mar 7, 2024

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

A Phase 3 interventional study of KC1036 and Irinotecan in Esophageal Squamous Cell Carcinoma, sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
490
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 402 studies in Esophageal Squamous Cell Carcinoma with a site in China — 175 open to participants now, 214 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Planned enrollment
32nd of 352
490 · median 70
Started
2024
with 50 others
Phase 3
52 of 402
20 open now
Primary completion
2026-12
later than 109 of 213 live
Registered
257th of 402
by date

Among the 402 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 32nd largest by planned enrollment of the 352 interventional ones that give a count, is one of 51 that started in 2024, is one of 52 in phase 3, reaches primary completion later than 109 of the 213 other live ones, and was the 257th registered.

Esophageal Squamous Cell Carcinoma

679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 270 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

175 of the 402 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

170 more — sign in →

All 175 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 181 Esophageal Squamous Cell Carcinoma studies recruiting now, 84 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma

Read the detailed description

This is a randomized, controlled, open-label, multicenter phase III trial. Patients with advanced recurrent or metastatic esophageal squamous cell carcinoma that has received PD-1 or PD-L1 inhibitors and at least second-line systemic therapy will be randomized at a 1: 1 ratio to receive KC1036 or the investigator's choice of chemotherapy (Irinotecan/Docetaxel/S-1) until confirmed disease progression assessed by the RECIST V1.1 standard, death, intolerable toxicity, initiation of a new anti-tumor therapy, other reasons leading to treatment discontinuation as specified by protocol.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 18 to 75 years;
  • or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma;
  • Patient with advanced recurrent or esophageal squamous cell carcinoma previously treated with a or PD-L1 inhibitor and at least systemic therapy;
  • At least one measurable tumor lesion according to 1.1;
  • performance status score of 0 or 1;
  • > 12 weeks;
  • ≥16.0 and weight≥40 kg ;
  • Adequate bone marrow, renal, and hepatic function;
  • Female patients of with a negative blood pregnancy test completed within 7 days before randomization;
  • Patients should participate in the study voluntarily and sign .

Exclusion criteria

Exclusion Criteria:

  • Any patient who is known to have untreated central nervous system (CNS) ;
  • Other kinds of within 5 years;
  • Gastrointestinal abnormalities;
  • Cardiovascular and cerebrovascular diseases;
  • Prior therapies with vascular targeting inhibitor;
  • Previously treated with Irinotecan, Docetaxel and Tegafur Gimeracil Oteracil Potassium;
  • Involved in other clinical trials within 4 weeks before enrollment;Prior anti-tumor therapies with radiotherapy, immunotherapy, operation within 4 weeks before enrollment;Prior anti-tumor therapies with small molecule targeting drugs within 2weeks or 5 half-lives (whichever is longer) before enrollment; Prior anti-tumor therapies with chemotherapy within 3 weeks or 5 half-lives (whichever is longer) before enrollment;
  • Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to 5.0 Grade 0 or 1;
  • Uncontrolled massive ascites, pleural or pericardial effusion;
  • Severe infection within 4 weeks prior to randomization (CTCAE > Grade 2);
  • Known history of (HIV) infection or current active or C infection;
  • Pregnant or lactating women;
  • Female subjects of and male subjects of reproductive capacity who do not agree to use measures during the study and for 6 months after the end of the study.
  • Other patients are not eligible for enrollment assessed by investigators.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
490 participants (estimated)

Study arms

  • Experimental
    KC1036

    KC1036 will be administrated.

    Drug: KC1036

  • Active comparator
    Investigator's choice of chemotherapy

    Irinotecan, Docetaxel or S-1 will be administrated.

    Drug: Irinotecan · Drug: Docetaxel · Drug: S-1

Interventions

  • DrugKC1036

    KC1036 60mg QD orally, before a meal, continuous administration, 21 days as a cycle

  • Irinotecan intravenously administered at 130-150 mg/m2 once every 2 weeks

  • Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks;

  • DrugS-1

    Drug pages: Tegafur · Gimeracil · Oxonic Acid

    S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle

    Also known as: Tegafur-gimeracil-oteracil potassium

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS is defined as the time from the start of randomization to death of any cause.

    Time frame: Baseline to study completion (approximately 24 months)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportions of patients with a complete response (CR) or partial response (PR) according to RECIST 1.1.

    Time frame: Baseline to study completion (approximately 24 months)

  2. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with a best overall complete response (CR), partial response (PR), or stable disease (SD) according to RECIST 1.1.

    Time frame: Baseline to study completion (approximately 24 months)

  3. Duration of Response (DOR)

    DOR is defined as the time from first documented objective response (complete response (CR)or partial response (PR)) to the date of first documented disease progression (PD) or death.

    Time frame: Baseline to study completion (approximately 24 months)

  4. Progression-free survival (PFS)

    PFS is defined as the time from the start of randomization to the date of the first documented progressive disease (PD) according to RECIST 1.1 or death.

    Time frame: Baseline to study completion (approximately 24 months)

  5. Incidence of Adverse events (AEs)

    Assessed by treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) during the treatment assessed by NCI CTCAE 5.0.

    Time frame: Baseline to 30 days after the last dose of study treatment

  6. Quality of Life (QOL) scores

    Quality of Life is a concept of comprehensive evaluation of the advantages and disadvantages of life. It mainly refers to the assessment of individual physiological, psychological and social functions, which is an important indicator of the effectiveness of medical and health care services.

    Time frame: Baseline to study completion (approximately 24 months)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2023
First posted
Jan 8, 2024
StartActual
Feb 5, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2027
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06194734
Lead sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Feb 5, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Mar 7, 2024

Study contacts

Jing Huang, Ph.D
Contact
huangjingwg@163.com
010-87788293
Jing Huang, Ph.D
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AXL/FLT3/VEGFR2 Inhibitor KC1036

Start the discussion